Search
Now showing items 1-10 of 22
Prostate specific membrane antigen and DNA damage repair in advanced prostate cancer
(Institute of Cancer Research (University Of London), 2022-03-31)
Identification and implementation of novel therapeutic strategies for advanced prostate cancer (PCa) remains an urgent, unmet clinical need. Prostate Specific Membrane Antigen (PSMA), a PCa biomarker, is currently being ...
Improving outcomes for the lung cancer patient with impaired lung function
(Institute of Cancer Research (University Of London), 2021-03-31)
Lung function impairment is common amongst patients with lung cancers. Identifying the patients that are most likely to benefit from anti-cancers therapies, without suffering significant toxicities, is central to improving ...
Applications of liquid biopsies in metastatic castration resistant prostate cancer
(Institute of Cancer Research (University Of London), 2020-02-29)
Despite many recent advances, treating advanced prostate cancer (PC) remains clinically challenging. The need for vaildated circulating biomarkers is well recognised in almost all cancers, including in PC. Whilst circulating ...
Biomarkers of therapy response and resistance in clear cell renal cell carcinoma AND Adaptive immune response to SARS-CoV-2 and COVID-19 vaccines in cancer patients
(Institute of Cancer Research (University Of London), 2022-04-30)
The cornerstone of treatment for metastatic clear cell renal cell carcinoma (ccRCC) are anti-VEGF and/or immune checkpoint inhibitors (CPI). However, there are no clinically implemented predictive biomarkers in any therapeutic ...
Developing biomarker guided treatments for colorectal cancer
(Institute of Cancer Research (University Of London), 2021-09-30)
Developing biomarker-driven treatments for oesophagogastric cancer
(Institute of Cancer Research (University Of London), 2020-08-31)
Introduction Despite recent advances in both genetic characterisation and development of novel targeted agents the outlook for advanced oesophagogastric (OG) cancers remain poor and there is a need for improved biomarker-driven ...
Exploring novel approaches to metastatic heterogeneity and clonal evolution
(Institute of Cancer Research (University Of London), 2021-12-31)
Background Alternative methods are required to optimise the clinical insights that may be derived from studies of cancer evolution and heterogeneity. Profiling a single biopsy of tumour tissue underestimates potential ...
Targeting androgen receptor splicing in lethal prostate cancer
(Institute of Cancer Research (University Of London), 2021-04-30)
Over the past decade, androgen receptor (AR) directed therapies such as abiraterone and enzalutamide have become the standard of care for treating advanced prostate cancer, improving both progression-free and overall ...
Optimising trial methodologies to maximise trial efficiencies: a case study in breast cancer radiotherapy trials
(Institute of Cancer Research (University Of London), 2020-01-31)
Background: In an era of falling local relapse rates, the risk-benefit ratio of adjuvant breast radiotherapy requires careful consideration, and the collection of normal tissue effect (NTE) data optimised. For patients at ...
Improving outcomes in older women with ovarian cancer
(Institute of Cancer Research (University Of London), 2021-09-30)
Background: Older women have disproportionately poorer survival outcomes for ovarian cancer. Sarcopenia, the loss of muscle mass and density is of interest as a potential non-invasive biomarker of frailty. Little is ...